Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 21285972)

  • 1. The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue.
    Oladipo O; Conlon S; O'Grady A; Purcell C; Wilson C; Maxwell PJ; Johnston PG; Stevenson M; Kay EW; Wilson RH; Waugh DJ
    Br J Cancer; 2011 Feb; 104(3):480-7. PubMed ID: 21285972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pleiotropic effects of CXC chemokines in gastric carcinoma: differences in CXCL8 and CXCL1 expression between diffuse and intestinal types of gastric carcinoma.
    Eck M; Schmausser B; Scheller K; Brändlein S; Müller-Hermelink HK
    Clin Exp Immunol; 2003 Dec; 134(3):508-15. PubMed ID: 14632759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ELR+ CXC chemokine expression in benign and malignant colorectal conditions.
    Rubie C; Frick VO; Wagner M; Schuld J; Gräber S; Brittner B; Bohle RM; Schilling MK
    BMC Cancer; 2008 Jun; 8():178. PubMed ID: 18578857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of the prognosis and immune infiltration for CXC chemokines in colorectal cancer.
    Yang X; Wei Y; Sheng F; Xu Y; Liu J; Gao L; Yang J; Sun X; Huang J; Guo Q
    Aging (Albany NY); 2021 Jul; 13(13):17548-17567. PubMed ID: 34233297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of SMAD4 Promotes Colorectal Cancer Progression by Recruiting Tumor-Associated Neutrophils via the CXCL1/8-CXCR2 Axis.
    Ogawa R; Yamamoto T; Hirai H; Hanada K; Kiyasu Y; Nishikawa G; Mizuno R; Inamoto S; Itatani Y; Sakai Y; Kawada K
    Clin Cancer Res; 2019 May; 25(9):2887-2899. PubMed ID: 30705034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial.
    Pentheroudakis G; Raptou G; Kotoula V; Wirtz RM; Vrettou E; Karavasilis V; Gourgioti G; Gakou C; Syrigos KN; Bournakis E; Rallis G; Varthalitis I; Galani E; Lazaridis G; Papaxoinis G; Pectasides D; Aravantinos G; Makatsoris T; Kalogeras KT; Fountzilas G
    PLoS One; 2015; 10(5):e0124612. PubMed ID: 25970543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of the expression and prognostic value of CXC chemokines in colorectal cancer.
    Yu L; Yang X; Xu C; Sun J; Fang Z; Pan H; Han W
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107077. PubMed ID: 33068862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCL8 expression is associated with advanced stage, right sidedness, and distinct histological features of colorectal cancer.
    Pennel KA; Quinn JA; Nixon C; Inthagard J; van Wyk HC; Chang D; Rebus S; ; Hay J; Maka NN; Roxburgh CS; Horgan PG; McMillan DC; Park JH; Roseweir AK; Steele CW; Edwards J
    J Pathol Clin Res; 2022 Nov; 8(6):509-520. PubMed ID: 35879507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stromal Expression of Vimentin Predicts the Clinical Outcome of Stage II Colorectal Cancer for High-Risk Patients.
    Liu LG; Yan XB; Xie RT; Jin ZM; Yang Y
    Med Sci Monit; 2017 Jun; 23():2897-2905. PubMed ID: 28611349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer.
    Cabrero-de Las Heras S; Martínez-Balibrea E
    World J Gastroenterol; 2018 Nov; 24(42):4738-4749. PubMed ID: 30479461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of CXC subfamily ligands in stage I-III patients with colorectal cancer.
    Li X; Zhong Q; Luo D; Du Q; Liu W
    PLoS One; 2019; 14(4):e0214611. PubMed ID: 30973890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Clinicopathological Significance of the CXCR2 Ligands, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8 in Gastric Cancer.
    Yamamoto Y; Kuroda K; Sera T; Sugimoto A; Kushiyama S; Nishimura S; Togano S; Okuno T; Yoshii M; Tamura T; Toyokawa T; Tanaka H; Muguruma K; Ohira M; Yashiro M
    Anticancer Res; 2019 Dec; 39(12):6645-6652. PubMed ID: 31810929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemokine (C-X-C motif) ligand 1 is associated with tumor progression and poor prognosis in patients with colorectal cancer.
    Zhuo C; Wu X; Li J; Hu D; Jian J; Chen C; Zheng X; Yang C
    Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29784873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPARC, FOXP3, CD8 and CD45 correlation with disease recurrence and long-term disease-free survival in colorectal cancer.
    Chew A; Salama P; Robbshaw A; Klopcic B; Zeps N; Platell C; Lawrance IC
    PLoS One; 2011; 6(7):e22047. PubMed ID: 21818290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemokine CXCL14 is associated with prognosis in patients with colorectal carcinoma after curative resection.
    Zeng J; Yang X; Cheng L; Liu R; Lei Y; Dong D; Li F; Lau QC; Deng L; Nice EC; Xie K; Huang C
    J Transl Med; 2013 Jan; 11():6. PubMed ID: 23294544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of CXC-chemokines and CXC-chemokine receptor type II constitute an autocrine growth mechanism in the epidermoid carcinoma cells KB and A431.
    Metzner B; Hofmann C; Heinemann C; Zimpfer U; Schraufstätter I; Schöpf E; Norgauer J
    Oncol Rep; 1999; 6(6):1405-10. PubMed ID: 10523720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic significance of CXCL1 hypersecretion by human colorectal cancer epithelia and myofibroblasts.
    le Rolle AF; Chiu TK; Fara M; Shia J; Zeng Z; Weiser MR; Paty PB; Chiu VK
    J Transl Med; 2015 Jun; 13():199. PubMed ID: 26104296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXC chemokines located in the 4q21 region are up-regulated in breast cancer.
    Bièche I; Chavey C; Andrieu C; Busson M; Vacher S; Le Corre L; Guinebretière JM; Burlinchon S; Lidereau R; Lazennec G
    Endocr Relat Cancer; 2007 Dec; 14(4):1039-52. PubMed ID: 18045955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of CXC group chemokines in lung cancer development and progression.
    Spaks A
    J Thorac Dis; 2017 Apr; 9(Suppl 3):S164-S171. PubMed ID: 28446981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the molecular interactions of interleukin-8 (CXCL8), growth related oncogen alpha (CXCL1) and a non-peptide antagonist (SB 225002) with the human CXCR2.
    Catusse J; Liotard A; Loillier B; Pruneau D; Paquet JL
    Biochem Pharmacol; 2003 Mar; 65(5):813-21. PubMed ID: 12628493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.